Unfortunately they also did a trial on pre-terms which found no benefit to cognitive development:
"Conclusions Supplementing the diets of preterm infants with a DHA dose of approximately 1% total fatty acids from days 2–4 until term CA showed no evidence of benefit at 7 years’ CA."
http://bmjopen.bmj.com/content/5/3/e007314.full
---------------------------
Abstract
Objective To determine if improvements in cognitive outcome detected at 18 months’ corrected age (CA) in infants born <33 weeks’ gestation receiving a high-docosahexaenoic acid (DHA) compared with standard-DHA diet were sustained in early childhood.
Design Follow-up of a multicentre randomised controlled trial. Randomisation was stratified for sex, birth weight (<1250 vs ≥1250 g) and hospital.
Setting Five Australian tertiary hospitals from 2008 to 2013.
Participants 626 of the 657 participants randomised between 2001 and 2005 were eligible to participate.
Interventions High-DHA (≈1% total fatty acids) enteral feeds compared with standard-DHA (≈0.3% total fatty acids) from age 2–4 days until term CA.
Primary outcome Full Scale IQ of the Wechsler Abbreviated Scale of Intelligence (WASI) at 7 years CA. Prespecified subgroup analyses based on the randomisation strata (sex, birth weight) were conducted.
Results 604 (92% of the 657 originally randomised) consented to participate (291 high-DHA, 313 standard-DHA). To address missing data in the 604 consenting participants (22 for primary outcome), multiple imputation was performed. The Full Scale IQ was not significantly different between groups (high-DHA 98.3, SD 14.0, standard-DHA 98.5, SD 14.9; mean difference adjusted for sex, birthweight strata and hospital −0.3, 95% CI −2.9 to 2.2; p=0.79). There were no significant differences in any secondary outcomes. In prespecified subgroup analyses, there was a significant sex by treatment interaction on measures of parent-reported executive function and behaviour. Scores were within the normal range but girls receiving the high-DHA diet scored significantly higher (poorer outcome) compared with girls receiving the standard-DHA diet.
Conclusions Supplementing the diets of preterm infants with a DHA dose of approximately 1% total fatty acids from days 2–4 until term CA showed no evidence of benefit at 7 years’ CA.
Trial registration number Australian New Zealand Clinical Trials Registry: ACTRN12606000327583.
- Forums
- ASX - By Stock
- CLV
- turn your baby into a genius
turn your baby into a genius, page-3
Featured News
Add CLV (ASX) to my watchlist
(20min delay)
|
|||||
Last
49.0¢ |
Change
-0.005(1.01%) |
Mkt cap ! $60.11M |
Open | High | Low | Value | Volume |
49.0¢ | 49.5¢ | 49.0¢ | $8.983K | 18.23K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 32789 | 49.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
50.0¢ | 44797 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 7695 | 2.000 |
1 | 796 | 1.995 |
1 | 796 | 1.990 |
1 | 796 | 1.985 |
1 | 796 | 1.980 |
Price($) | Vol. | No. |
---|---|---|
2.030 | 7190 | 2 |
2.040 | 2620 | 3 |
2.050 | 16114 | 2 |
2.060 | 2764 | 2 |
2.070 | 3787 | 3 |
Last trade - 15.45pm 15/11/2024 (20 minute delay) ? |
Featured News
CLV (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online